Skip to main content

Table 2 Incremental cost-effectiveness ratios (ICERs) for 5 years of drug therapy or no therapy, T-score = -1.8.

From: Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia

  

Cost ($)

Effectiveness (QALY)

ICER* ($/QALY)

Age

Therapy

Total

Δ

Total

Δ

 

55

Conservative care

20,342

-

14.270

-

-

 

Raloxifene

24,169

3,827

14.351

0.081

47,247

 

Alendronate

24,370

201

14.303

-0.048

Dominated

60

Conservative care

16,773

-

12.747

-

 
 

Raloxifene

20,499

3,726

12.823

0.076

49,026

 

Alendronate

20,748

249

12.782

-0.041

dominated

65

Conservative care

13,541

-

11.131

-

-

 

Raloxifene

17,240

3,699

11.196

0.065

56,908

 

Alendronate

17,471

231

11.166

-0.030

dominated

70

Conservative care

10,643

-

9.474

-

 
 

Raloxifene

14,355

3,712

9.528

0.054

68,741

 

Alendronate

14,513

158

9.505

-0.023

dominated

75

Conservative care

8,084

-

7.808

-

-

 

Alendronate

11,860

3,776

7.833

0.025

dominated*

 

Raloxifene

11,861

3,777

7.845

0.037

102,081

  1. The ICERs were calculated using additional significant figures in the incremental cost and QALYs. Abbreviations: QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio
  2. • dominated by extended dominance (raloxifene has greater effectiveness and a lower cost-effectiveness ratio)
Back to article page

BMC Women's Health

ISSN: 1472-6874

Contact us